Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering

Reuters12-11

<a href="https://laohu8.com/S/CTOR">Citius Oncology</a> Announces Warrant and Share Issuance in $18 Million Offering

Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR™, a cancer immunotherapy for cutaneous T-cell lymphoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120197), on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590565455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 06:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590565455","market":"nz","top_or_hot":-1,"title":"Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> Announces Warrant and Share Issuance in $18 Million Offering\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR™, a cancer immunotherapy for cutaneous T-cell lymphoma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120197), on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Oncology Announces Warrant and Share Issuance in $18 Million Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 06:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> Announces Warrant and Share Issuance in $18 Million Offering\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR™, a cancer immunotherapy for cutaneous T-cell lymphoma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120197), on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTOR","symbol_name":"CITIUS ONCOLOGY INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4PPKCz:1","article_id":"2590565455","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590565455","pubTimestamp":1765405785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR, a cancer immunotherapy for cutaneous T-cell lymphoma.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTOR":"CITIUS ONCOLOGY INC","CTXR":"Citius Pharmaceuticals, Inc.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Citius Oncology宣布发行1800万美元的认股权证和股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTOR":0.9,"CTXR":0.9},"content_text":"Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering\n    \n\n        Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR™, a cancer immunotherapy for cutaneous T-cell lymphoma.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120197), on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590565455","isCrawlerRequest":true}